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Abstract: The forkhead box proteins A1 and A2 (Foxa1 and Foxa2)
are transcription factors with critical roles in establishing the devel-
opmental competence of the foregut endoderm and in initiating liver
speciﬁcation. Using conditional gene ablation during a later phase of
liver development, we show here that deletion of both Foxa1 and
Foxa2 (Foxa1/2) in the embryonic liver caused hyperplasia of the bil-
iary tree. Abnormal bile duct formation in Foxa1/2-deﬁcient liver
was due, at least in part, to activation of IL-6 expression, a prolifer-
ative signal for cholangiocytes. The glucocorticoid receptor is a neg-
ative regulator of IL-6 transcription; in the absence of Foxa1/2, the
glucocorticoid receptor failed to bind to the IL-6 promoter, causing
enhanced IL-6 expression. Thus, after liver speciﬁcation, Foxa1/2
are required for normal bile duct development through prevention
of excess cholangiocyte proliferation. Our data suggest that Foxa1/2
function as terminators of bile duct expansion in the adult liver
through inhibition of IL-6 expression.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
The liver develops from the ventral foregut endoderm. This struc-
ture gives rise to a tissue bud that invades the septum transver-
sum and from which originates the liver and the intrahepatic
biliary tree. At the time of liver speciﬁcation, liver stem cells dif-
ferentiate into hepatoblasts, the precursors of hepatocytes and
cholangiocytes. Hepatoblasts in contact with the mesenchyma
surrounding the portal vein branches, organize into a single lay-
ered sleeve of small ﬂat epithelial cells, called ductal plates. Duc-
tal plates are ﬁrst duplicated by a second layer of cells over
variably long segments of their perimeter and then dilate to form
tubular structures that are then incorporated into the nascent
portal space. Once incorporated into the portal space, the imma-
ture tubules are remodelled to form individual bile ducts, whileJournal of Hepatology 20
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.by apoptosis [1,2].
Several transcription factors (HNF1b, HNF4, and HNF6) and
signaling pathways (Jagged1/Notch2, Hedgehog, TGFb, Wnt/b-
catenin, and FGF) that regulate the development of the intrahe-
patic biliary epithelium have been identiﬁed, but the signals that
arrest bile duct formation at the appropriate developmental time
are not known. In a recent issue of the Journal of Clinical Investi-
gation, Dr. Li, from Klaus Kaestner’s lab [3], provides convincing
evidence that the Foxa1 and Foxa2 transcription factors may
actually function as terminators of bile duct expansion (see
Fig. 1).
Foxa1 and Foxa2 (previously known as HNF3) belong to a
group of liver speciﬁc transcription factors that also includes
the above mentioned HNF1a HNF1b, HNF4, HNF6, and C/EBPa,b.
The Foxa family of transcription factors (from forkhead box pro-
tein A) controls embryonic development and organogenesis in a
number of organs, including the liver and pancreas. If both Foxa1
and 2 are deleted, no liver is formed, indicating that, in the mouse
embryo, Foxa transcription factors play a critical role in establish-
ing the developmental competence of the foregut endoderm and
in initiating liver speciﬁcation [3].
Using a conditional gene ablation approach, Li and colleagues
[3] showed that deletion of Foxa1/2 after initial liver speciﬁca-
tion caused biliary hyperplasia, an increased number of dysmor-
phic and dilated biliary structures, along with an increased
deposition of ﬁbrous tissue. Cholangiocyte proliferation was
drastically increased. These changes were not associated with
changes in other pathways involved in biliary development, such
as Wnt, Notch, and Hedgehog. On the other hand, persistently
elevated levels of interlukin-6 (IL-6) expression were found in
the biliary epithelium that also expressed increased STAT 3
and p42/44 MAPK and IL-6-dependent genes. These changes
were prevented by administration of inhibitory anti-IL-6
antibodies.
Foxa1/2 are ‘‘pioneer” factors that are able to open the chro-
matin and enhance the binding of other transcription factors to
their target genes. For instance, Foxa1/2 proteins facilitate the
binding of nuclear hormone receptors to their targets. One such
receptor is the glucocorticoid receptor (GR). The IL-6 promoter
contains closely spaced binding sites for Foxa1/2, GR and NF-
jB. GR suppresses the IL-6 promoter, but NF-jB can replace GR
and stimulate IL-6 transcription. Li et al. showed that Foxa1/2
are required to enable the GR to bind to the IL-6 promoter. In
their absence, NF-jB will bind to the IL-6 promoter instead of
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Fig. 1. Ductular proliferation and the expansion of ‘‘reactive cholangiocytes” is a common compensatory and reparative response to liver damage (A). Reactive
cholangiocytes, also called ‘‘liver progenitor cells” because of their ability to differentiate into hepatocytes, are thought to originate from epithelial cells lining cholangioles
and ducts of Hering. Reactive cholangiocytes generate a number of growth factors, chemokines, and cytokines generating a network of autocrine and paracrine signals that
play a key role in liver repair and cross talk with the other cell types of the hepatic reparative complex (mesenchymal cells, inﬂammatory cells, endothelial cells) (B). The
molecular mechanisms regulating the activation of reactive cholangiocytes are not known. The paper from Li et al. begins to shed light on these mechanisms showing that
release of Foxa1/2 repression is essential to allow transcription of IL-6 in developing and reactive biliary cells. Foxa1/2 are ‘‘pioneer” factors, able to open the chromatin and
enhance the binding of other transcription factors, such as the glucocorticoid receptor (GR), to their target genes. The IL-6 promoter contains closely spaced binding sites for
Foxa1/2, GR, and NF-jB. GR suppresses the IL-6 promoter. Li et al. showed that Foxa1/2 are required to enable the GR to bind to the interlukin-6 (IL-6) promoter. In their
absence, NF-jB, will bind to the IL-6 promoter instead of GR, resulting in stimulation of IL-6 production. It is tempting to speculate that similar models may apply to several
of the other paracrine and autocrine factors generated by reactive cells (C).
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Are these ﬁndings relevant for human liver diseases? Foxa1
and Foxa2 remain expressed in normal hepatocytes and cholan-
giocytes in adulthood [3], suggesting that these transcription
factors may act as repressors of IL-6 expression also in the adult
liver. In contrast to normal biliary cells, reactive cholangiocytes
are known to secrete a large amount of IL-6 [4]. Li and colleagues
showed that in mice with experimental obstructive cholestasis,
Foxa1 and 2 expression decreases, concomitantly with an
increase in IL-6 expression [3]. This inﬂammatory cytokine is an
important autocrine and paracrine survival factor for liver epithe-
lial cells [5,6]. In fact, mortality following bile duct ligation is
increased in mice defective for IL-6.
Ductular proliferation and expansion of the cholangiocyte
compartment is a compensatory response to many acute and
chronic forms of liver diseases, from cholangiopathies to viral
hepatitis and fulminant hepatitis. When the proliferative ability
of hepatocytes is impaired, cells from the canals of Hering give
rise to progenitor cells/reactive cholangiocytes capable of gener-
ating both biliary cells and hepatocytes.
In addition to IL-6, a number of autocrine and paracrine fac-
tors, including the epidermal growth factor (EGF), hepatocyte
growth factor (HGF), insulin-like growth factor-1 (IGF-1), vascu-
lar endothelial growth factor (VEGF), and neurotrophins and
estrogens, are able to stimulate biliary epithelia proliferation
[7–9]. Furthermore, in response to liver damage, reactive cholan-
giocytes also secrete IL-1b, IL-8, TNFa, IFNc, monocyte chemotac-
tic protein-1 (MCP-1), cytokine-induced neutrophil chemo
attractant (CINC), nitric oxide (NO), endothelin-1 (ET-1), platelet
derived growth factor-BB (PDGF-BB), transforming growth factor-
b2 (TGF-b2), connective tissue growth factor (CTGF), and VEGF-A
and C [8,9]. These factors have important paracrine effects on
hepatic stellate cells (HSC), portal ﬁbroblasts, inﬂammatory cells,
endothelial cells, and as well as on mesenchymal and endothelial
precursors [8,9]. It is therefore not surprising that Foxa1/2 defec-
tive mice exhibit increased portal ﬁbrosis, likely as a result of the
paracrine effects of IL-6. In human liver disease, the extent of
ductular reaction is known to correlate with the extent of portal
ﬁbrosis [10,11].
Unfortunately, the mechanisms responsible for the ‘‘activa-
tion” of reactive cholangiocytes are not well understood. It is
tempting to speculate that in cholangiocytes exposed to biliary
damage, the release of Foxa1/2-mediated repression enables the
activation of the reactive/progenitor cells. Several of the above
mentioned factors are also transitorily expressed by ductal plate
cells during development. Recent observations underscore the
importance of morphogenesis pathways such as Hh, Wnt, and
Notch in progenitor cell-mediated liver repair [10,12,13]. Thus,
liver repair mechanisms appear to recapitulate ontogenesis, and
as we increase our knowledge of liver development, we fosterJournal of Hepatology 201our understanding of the pathophysiology of the diseases of
adulthood. Or, in better words ‘‘So we beat on. . ...borne back
ceaselessly into the past” [14].
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